ALECR Stock Overview
Provides various drug discovery services to pharmaceutical, biopharmaceutical, and biotechnology companies France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Eurofins-Cerep SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €19,300.00 |
| 52 Week High | €23,800.00 |
| 52 Week Low | €18,400.00 |
| Beta | 0.63 |
| 11 Month Change | 0.52% |
| 3 Month Change | -8.96% |
| 1 Year Change | -22.80% |
| 33 Year Change | 3.76% |
| 5 Year Change | 211.29% |
| Change since IPO | 312.83% |
Recent News & Updates
Investors Aren't Entirely Convinced By Eurofins-Cerep SA's (EPA:ALECR) Revenues
Oct 18
Eurofins-Cerep SA's (EPA:ALECR) Subdued P/S Might Signal An Opportunity
Jun 26Shareholder Returns
| ALECR | FR Life Sciences | FR Market | |
|---|---|---|---|
| 7D | 0% | -5.2% | -1.7% |
| 1Y | -22.8% | 2.8% | -1.9% |
Return vs Industry: ALECR underperformed the French Life Sciences industry which returned 2.8% over the past year.
Return vs Market: ALECR underperformed the French Market which returned -1.9% over the past year.
Price Volatility
| ALECR volatility | |
|---|---|
| ALECR Average Weekly Movement | 7.3% |
| Life Sciences Industry Average Movement | 5.9% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.4% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALECR's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALECR's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 228 | Damien Vielliard | www.eurofins.fr/cerep/ |
Eurofins-Cerep SA provides various drug discovery services to pharmaceutical, biopharmaceutical, and biotechnology companies France and internationally. The company’s research services include compound management, and high-throughput screening and profiling. The company was formerly known as Cerep SA and changed its name to Eurofins-Cerep SA in June 2014.
Eurofins-Cerep SA Fundamentals Summary
| ALECR fundamental statistics | |
|---|---|
| Market cap | €97.35m |
| Earnings (TTM) | €7.64m |
| Revenue (TTM) | €44.07m |
12.7x
P/E Ratio2.2x
P/S RatioIs ALECR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALECR income statement (TTM) | |
|---|---|
| Revenue | €44.07m |
| Cost of Revenue | €23.86m |
| Gross Profit | €20.21m |
| Other Expenses | €12.57m |
| Earnings | €7.64m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.51k |
| Gross Margin | 45.86% |
| Net Profit Margin | 17.33% |
| Debt/Equity Ratio | 0.005% |
How did ALECR perform over the long term?
See historical performance and comparison